Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have been assigned a consensus recommendation of “Hold” from the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $21.29.
AMAG has been the subject of several recent analyst reports. Cowen set a $19.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, November 1st. BidaskClub upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 5th. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. B. Riley restated a “buy” rating and issued a $20.50 price target (down previously from $29.00) on shares of AMAG Pharmaceuticals in a research note on Friday, December 14th. Finally, JPMorgan Chase & Co. lowered AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and cut their price target for the company from $20.00 to $18.00 in a research note on Tuesday, November 6th.
A number of hedge funds have recently bought and sold shares of AMAG. Advisors Asset Management Inc. boosted its holdings in AMAG Pharmaceuticals by 791.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 52,356 shares during the last quarter. HighPoint Advisor Group LLC acquired a new stake in AMAG Pharmaceuticals in the 3rd quarter worth about $188,000. Robeco Institutional Asset Management B.V. boosted its holdings in AMAG Pharmaceuticals by 2.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 995,319 shares of the specialty pharmaceutical company’s stock worth $19,908,000 after buying an additional 19,571 shares during the last quarter. Alps Advisors Inc. boosted its holdings in AMAG Pharmaceuticals by 22.5% in the 3rd quarter. Alps Advisors Inc. now owns 61,003 shares of the specialty pharmaceutical company’s stock worth $1,220,000 after buying an additional 11,187 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in AMAG Pharmaceuticals by 18.7% in the 3rd quarter. Acadian Asset Management LLC now owns 608,968 shares of the specialty pharmaceutical company’s stock worth $12,181,000 after buying an additional 95,955 shares during the last quarter.
Shares of AMAG Pharmaceuticals stock traded up $0.09 on Wednesday, hitting $16.22. The company’s stock had a trading volume of 1,359 shares, compared to its average volume of 470,063. The company has a quick ratio of 2.72, a current ratio of 2.86 and a debt-to-equity ratio of 0.34. AMAG Pharmaceuticals has a 1 year low of $11.95 and a 1 year high of $26.10. The firm has a market cap of $557.13 million, a PE ratio of -2.84 and a beta of 0.45.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Read More: Moving Average (MA)
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.